Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry-Reference-Cited by-同舟云学术

Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry

Published:2018-01-12 Issue:1 Volume:13 Page:
ISSN:1746-1596
Container-title:Diagnostic Pathology
language:en
Short-container-title:Diagn Pathol

Author:

Bonaparte Eleonora,Pesenti Chiara,Fontana Laura,Falcone Rossella,Paganini Leda,Marzorati Anna,Ferrero Stefano,Nosotti Mario,Mendogni Paolo,Bareggi Claudia,Sirchia Silvia Maria,Tabano Silvia,Bosari Silvano,Miozzo Monica

Funder

Ministero della Salute - Regione Lombardia

IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13000-017-0683-7.pdf

Reference29 articles.

1. Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382:709–19.

2. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121–7.

3. Inoue A, Kobayashi K, Maemondo M, et al. North-East Japan study group: updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54–9.

4. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–99.

5. Rosell R, Carcereny E, Gervais R, et al. Spanish lung cancer group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–2346.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maximizing Analytical Performance in Biomolecular Discovery with LC-MS: Focus on Psychiatric Disorders;Annual Review of Analytical Chemistry;2024-07-17

2. Precision medicine in oncology: role and prospects of mass spectrometry;Bulletin of Siberian Medicine;2024-07-11

3. MALDI Imaging Mass Spectrometry of High-Grade Gliomas: A Review of Recent Progress and Future Perspective;Current Issues in Molecular Biology;2023-01-18

4. Non‐small cell lung cancer in China;Cancer Communications;2022-09-08

5. Identification and characterization of post-translational modifications: Clinical implications;Molecular Aspects of Medicine;2022-08